Solid Biosciences (SLDB) Other Non-Current Liabilities (2018 - 2024)
Solid Biosciences' (SLDB) quarterly Other Non-Current Liabilities came in at $3.4 million in Q3 2024, up 3441.67% quarter-over-quarter from $96000.0 in Q4 2022.
Solid Biosciences (SLDB) Other Non-Current Liabilities (2018 - 2024) Analysis & Trends
Solid Biosciences has disclosed Other Non-Current Liabilities across 4 years of filings, most recently posting $3.4 million for Q3 2024.
- Other Non-Current Liabilities for Q3 2024 came in at $3.4 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2024 was $3.4 million (changed N/A YoY), and the FY2022 annual result was $96000.0, changed N/A from the prior year.
- Other Non-Current Liabilities came in at $3.4 million for Q3 2024 at Solid Biosciences, up from $96000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $3.4 million in Q3 2024 to a low of $96000.0 in Q4 2022.
- The 3-year median for Other Non-Current Liabilities is $1.3 million (2020), against an average of $1.6 million.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Solid Biosciences | 789.54 Mn | 408.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 3.40 Mn |
| Dec 31, 2022 | 96,000.00 |
| Dec 31, 2020 | 1.30 Mn |
| Dec 31, 2018 | 1.07 Mn |
| Sep 30, 2018 | 1.10 Mn |
| Jun 30, 2018 | 499,000.00 |
| Mar 31, 2018 | 365,000.00 |